Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as hematologic and solid tumors, including nasopharyngeal carcinoma. The company is also developing next-generation CAR T immunotherapies for patients with hematologic malignancies and solid tumors, including ATA2271 and ATA3271 for mesothelin; and ATA2431 and ATA3219 for B-cell malignancies, as well as ATA188 for the treatment of multiple sclerosis. In addition, it develops ATA368 program for patients with human papillomavirus associated cancers. Atara Biotherapeutics, Inc. has a license agreement with Memorial Sloan Kettering Cancer Center; license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute; and strategic collaboration with H. Lee Moffitt Cancer Center, as well as Bayer AG for mesothelin-targeted CAR T-cell therapies for solid tumors. The company was incorporated in 2012 and is headquartered in South San Francisco, California.

Atara Biotherapeutics, Inc.

Atara Biotherapeutics Inc., is a leading allogeneic T-cell immunotherapy company pioneering the development of transformative off-the-shelf therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases.  

With our lead program receiving marketing authorization in Europe, Atara is the most advanced allogeneic T-cell immunotherapy company and intends to rapidly deliver off-the-shelf treatments to patients with high unmet medical need. Our platform leverages the unique biology of EBV T cells and has the capability to treat a wide range of EBV-associated diseases, or other serious diseases through incorporation of engineered CARs (chimeric antigen receptors) or TCRs (T-cell receptors). Atara is applying this one platform, which does not require TCR or HLA gene editing, to create a robust pipeline including: tab-cel for Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD) and other EBV-driven diseases; ATA188, a T-cell immunotherapy targeting EBV antigens as a potential treatment for multiple sclerosis; and multiple next-generation chimeric antigen receptor T-cell (CAR-T) immunotherapies for both solid tumors and hematologic malignancies.  

Kleiner Perkins

Celgene

DAG Ventures

Domain Associates

EcoR1 Capital

Alexandria

Amgen Ventures

Atara Biotherapeutics

Today Atara announced the publication of the pivotal ALLELE tab-cel® study data in patients with relapsed or refractory Epstein-Barr virus (#EBV) positive post-transplant lymphoproliferative disease (#PTLD) in The Lancet Oncology, representing the first Phase 3 results published for an #allogeneic #Tcell therapy. 

➡Press release: https://bit.ly/4bkXbT1 

It was a pleasure highlighting the latest developments and potential of Atara's #allogeneic #CART programs for hematological malignancies and autoimmune diseases at #JPM24. https://bit.ly/3vxNksE

Next week, our CEO Pascal Touchon is heading to San Francisco to share Atara's latest pipeline progress & key development milestones at the J.P. Morgan Annual Healthcare Conference on Thursday, January 11 at 9:45 a.m. PT: https://bit.ly/3H8hXrd 

At this year's American Society of Hematology Annual Meeting, Atara will present positive preclinical data on ATA3431, our investigational next-generation #allogeneic CD20/CD19-targeted #CAR #EBV T-cell therapy for the treatment of B-cell malignancies. For more: https://bit.ly/3GA8b0O #ASH23  

COM:ATARABIO

Atara Biotherapeutics Inc

Last Close

8.72

14/02 21:00

Market Cap

44.24M

Beta: -

Volume Today

57.51K

Avg: -

People Not Available